Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 28th Preview)
-
Cancer diagnostics approval and commercialization rights
Freenome said the FDA has approved its SimpleScreen blood-based colorectal cancer screening test, marking the company’s first commercial authorization. The test is for adults 45 and older at average risk and uses a blood draw to detect signals linked to colorectal cancer from cell-free DNA. Under a commercialization deal, Abbott will have exclusive rights to market SimpleScreen in the US beginning this fall. Freenome, which IPO’d last week, said the approval also supports Medicare coverage criteria and anticipates inclusion in American Cancer Society guidance. The readout matters for the colorectal screening market because SimpleScreen is designed to complement Abbott’s Cologuard offering, expanding options for patients who may not complete stool-based screening.
-
Immunology M&A reshapes autoimmune pipeline
Argenx agreed to acquire Forte Biosciences for $2.2 billion in an all-cash deal, valuing Forte at $77 per share. The purchase brings Forte’s anti-CD122 monoclonal antibody FB102 into Argenx’s pipeline and follows early clinical data in vitiligo. FB102 delivered a 29.6% improvement in a facial vitiligo score in a Phase Ib trial, and Argenx said positive Phase Ib results also emerged in coeliac disease. Argenx expects Phase II data in coeliac disease in the second half of 2026 and positioned the program as “pipeline-in-a-product” given potential in alopecia areata and other immune-mediated diseases. The deal is not subject to financing conditions and will be funded from cash on hand, pending tender support and Hart-Scott-Rodino clearance.
-
FDA cautions on cell therapy efficacy ahead of advisory vote
FDA staff told advisers that Capricor’s deramiocel data do not adequately demonstrate the treatment works in Duchenne muscular dystrophy ahead of a Cellular, Tissue and Gene Therapies advisory committee meeting. The agency’s briefing documents argue the pivotal study’s design and analysis did not meet objectives for identifying efficacy. Capricor said previously that the Phase 3 trial met primary and secondary endpoints, but the FDA’s critique raises the risk of further scrutiny on how efficacy endpoints were interpreted and validated. The company is preparing for the July 29 discussion as it tries to navigate a path to potential approval for deramiocel in a space where regulators often require clear, reproducible efficacy signals.
-
FDA challenges on melanoma gene therapy for systemic benefit
FDA staff reiterated concerns that Replimune’s investigational RP1 program for melanoma lacks sufficient evidence to support approval. In briefing documents for a forthcoming advisory committee meeting, the agency criticized the pivotal trial design as inadequate to separate the drug’s efficacy from the background of prior PD-1 inhibitor exposure. The FDA also questioned whether locally injected RP1 produces systemic benefits, arguing that the single-arm study is not enough to evaluate the drug’s independent contribution to outcomes. Replimune responded that randomizing patients to RP1 versus placebo on top of PD-1 therapy is “not feasible or ethical” for patients whose cancer has stopped responding to PD-1 inhibitors, where no benefit from continued anti-PD-1 monotherapy has been established.
-
US trial network push uses regulatory quality signals
CRO Veristat urged the FDA to use first-in-human (FIH) clinical hold rates as a quality metric when selecting organizations for its new qualified research institution (QRI) network. The argument is that hold rate reflects cross-disciplinary IND preparation quality, including clinical, nonclinical, and CMC components. Veristat suggested the FDA compare hold rates over a defined recent period and contextualize them with IND submission counts and modalities. The company tied the proposal to the FDA’s broader “Operational Trailblazer” effort to expand early-stage trials in the US. If adopted, the approach could influence which sites sponsors choose for FIH protocol development, potentially tightening the feedback loop between IND submission discipline and trial initiation speed.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.